CJC-1295 No DAC vs Tesamorelin (TH9507) Peptide

CJC-1295 No DAC (also known as Modified GRF 1-29) and Tesamorelin are both synthetic analogues of growth hormone releasing hormone (GHRH), and both act by stimulating the GHRH receptor (GHRHR) to increase pulsatile GH secretion. Their mechanistic similarity makes them directly comparable as research tools, but their pharmacokinetic profiles and evidence bases are markedly different. CJC-1295 No DAC — the form without the Drug Affinity Complex — has a short half-life of approximately 30 minutes in vivo, which makes it suitable for studies where pulsatile, time-limited GH release is the experimental goal. Tesamorelin (TH9507) incorporates a trans-3-hexenoic acid modification at the N-terminus that confers metabolic stability and extends its half-life beyond that of native GHRH. Critically, Tesamorelin carries the strongest clinical evidence base of any GHRH analogue: it is FDA-approved (as Egrifta) for HIV-associated lipodystrophy, supported by Phase III randomised controlled trials demonstrating significant visceral fat reduction. Researchers choosing between these compounds typically select CJC-1295 No DAC for studies prioritising pulsatility and short-window GH kinetics, and Tesamorelin for studies where sustained GHRHR agonism or visceral adipose reduction is the primary endpoint.